Park innovator Eco-Inject has secured £5.2 million in equity funding, led by Adjuvo. The investment will enable Eco-Inject to scale up production, meet regulatory standards and expand into the growing global market.
Autoinjectors were once mainly used for emergency treatments, but they are now widely used to deliver a growing range of medicines which patients can inject themselves, including GLP-1 drugs. More than 500 million autoinjectors are used each year, with demand expected to rise to 2 billion by 2030. Despite this growth, many devices are still complex, plastic-heavy and costly to make and dispose of.
Eco-Inject has rebuilt the autoinjector from scratch, using a simpler, bio-based design that reduces carbon emissions without increasing cost. The platform works with existing pre-filled syringes, making it easy for pharma companies to adopt without disruption.
Founder and CTO John Palmer-Felgate said the investment validates a design-led approach focused on removing complexity rather than simply “greening” an existing product.
Eco-Inject expects its first customers to be in Europe and the US, with plans to serve a global market as demand continues to grow.